Capstan Therapeutics' Laura Shawver on 'decorating' LNPs with antibodies
Dr. Shawver describes how Capstan plans to achieve in-vivo CAR-T by utilizing LNPs to deliver mRNA to lymphocytes in the body.
Also look for unique social pages for BiotechTV U.
#1. Pfizer’s CEO on Q2 earnings.
​
#2. Moderna CEO Stéphane Bancel on Moderna’s business at its R&D Day in New York
​
#3. UPenn’s Bruce Levine discusses the progress of CAR-T
​
#4. Learning about gene writing at Tessera Therapeutics
#5. Visiting Bayer’s Research and Innovation Center in Kendall Square